Sumitomo Pharma America

Jun 12, 2025

Sumitomo Pharma America Announces that Nuvisertib (TP-3654) Has Received FDA Fast Track Designation for the Treatment of Myelofibrosis

Dec 23, 2024

Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Dec 03, 2024

Sumitomo Pharma America and Actor Holly Robinson Peete Encourage People with Overactive Bladder to Speak Up and Seek Treatment

Jul 15, 2024

Sumitomo Pharma Announces that DSP-5336 Has Received FDA Fast Track Designation for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Jun 14, 2024

Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress

May 07, 2024

Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting

Mar 12, 2024

Sumitomo Pharma Announces Availability of ORGOVYX® (relugolix) in Canada, the First and Only Oral Androgen Deprivation Therapy Treatment for Men with Advanced Prostate Cancer